The effect of extracellular vesicles on the regulation of mitochondria under hypoxia

Yaodan Zhang¹, Jin Tan¹, Yuyang Miao² and Qiang Zhang¹

Abstract
Mitochondria are indispensable organelles for maintaining cell energy metabolism, and also are necessary to retain cell biological function by transmitting information as signal organelles. Hypoxia, one of the important cellular stresses, can directly regulates mitochondrial metabolites and mitochondrial reactive oxygen species (mROS), which affects the nuclear gene expression through mitochondrial retrograde signal pathways, and also promotes the delivery of signal components into cytoplasm, causing cellular injury. In addition, mitochondria can also trigger adaptive mechanisms to maintain mitochondrial function in response to hypoxia. Extracellular vesicles (EVs), as a medium of information transmission between cells, can change the biological effects of receptor cells by the release of cargo, including nucleic acids, proteins, lipids, mitochondria, and their compositions. The secretion of EVs increases in cells under hypoxia, which indirectly changes the mitochondrial function through the uptake of contents by the receptor cells. In this review, we focus on the mitochondrial regulation indirectly through EVs under hypoxia, and the possible mechanisms that EVs cause the changes in mitochondrial function. Finally, we discuss the significance of this EV-mitochondria axis in hypoxic diseases.

Facts
- Hypoxia directly regulates mitochondrial metabolism and mitochondrial compositions via HIF1α, and mitochondria can also trigger quality control mechanisms to adapt to hypoxia.
- As a medium of information transmission between cells, extracellular vesicles can be regulated by hypoxia.
- Extracellular vesicles containing mitochondria and mitochondrial DNA transferred between cells to induce inflammatory response of receptor cells.
- Extracellular vesicles can also regulate mitochondrial function through a variety of mechanisms.

Open Questions
- Which specific substances contained in EVs plays a key role in the regulation of mitochondria?
- What are the specific mechanisms by which the contents of EVs enter directly into the mitochondria of recipient cells?
- Whether is there a mutual regulatory relationship among several pathways of mitochondrial transfer between cells, including EVs, tunneling nanotubes, exophers etc?

Introduction
Mitochondria are important organelles for maintaining cell energy metabolism. However, researchers over the last few decades have shown that mitochondria are necessary to maintain cell biological function by transmitting information as signal organelles. mROS and the change of metabolites induced by hypoxic may cause the changes of nuclear gene expression, which is called mitochondrial retrograde signaling (MtRS) pathways.
Mitochondria trigger multiple mechanisms to adapt to hypoxia, including the changes of oxidative phosphorylation, mitophagy, mitochondrial fission, and fusion.

Hypoxia plays a crucial role in progression of disease as the main pathological mechanism of hypoxic diseases. In hypoxic diseases such as tumor, ischemic disease, mitochondria have multifunctional effects on cell damage and disease progression, and targeting mitochondria could be a therapeutic direction. For instance, it has been shown that metformin can inhibit cellular respiration and mitochondrial complex I activity of tumor cell to inhibit cancer progression, and the combination of metformin and PDI checkpoint blockers led to increased tumor-infiltrating T cells function and tumor clearance. Thus, targeting mitochondria through drug intervention may change the disease process that are mediated by dysfunctional mitochondria.

In recent years, it has been found that EVs can be released by almost all types of cells. Hypoxia causes significant changes of the cargo, quantitative impact of secretion and the function of EVs. Mitochondria and their components can also spread between cells through EVs and other pathways, promoting inflammation, cancer progression, and the recovery of cellular function of damaged mitochondria. As a carrier of intercellular information transmission, EVs can carry active molecules and act on mitochondria of receptor cells, which cause the change of mitochondrial function. Thus, the change of mitochondrial function and composition is not only the result of direct stimulation by hypoxia, but also likely the indirectly effect of EVs released by different physiological and pathological states of cells. We will review how EVs and their contents change mitochondrial composition, function, and possible mechanisms, which will provide ideas for the future application of EVs targeting mitochondrial pathway in hypoxic status.

**Extracellular vesicles, hypoxia and mitochondria**

**Extracellular vesicles**

EVs are membrane vesicles secreted by almost all cells, which can be divided into two main categories: exosomes and microvesicles, based on their biogenesis. Microvesicles are formed by the outward budding of the plasma membrane, whereas exosomes are originated from intraluminal vesicles (ILVs), which formed by the inward budding of endosomal membrane in multivesicular endosomes (MVEs) and released by the fusion of MVEs and plasma membrane. Different EV subtypes have different sizes, density ranges, and contents, but they cannot be fully distinguished because of the overlap and technical limitations. Although the physical characteristics, biogenesis and contents of different subpopulations of EVs are different, the biology of uptake by target cells are similar. Researchers have found that EVs play an increasingly important role in the intercellular communication by exchanging contents between cells. In addition, each cell type may secrete different contents of EVs according to its physiological and stress state. Also, the production, secretion and uptake of EVs can be affected well, which results in the corresponding biological changes of receptor cells.

**Hypoxia**

Hypoxia refers to oxygen limitation in tissue. In animals, oxygen can be exchanged in the lungs, and more than 95% of the oxygen will enter the capillaries through the exchange system of alveolar-capillary. Most tissues of the body obtain sufficient oxygen from capillaries to meet their basic metabolic requirements. Developing tumors rapidly outgrow their oxygen supply, the hypoxic tumor microenvironment ([PO2] < 10 mmHg, 1 mmHg O2 = 0.13% O2) is formed. It has been known that hypoxic condition promotes tumor progression, and it is necessary to improve hypoxic condition to treat tumor.

Different tissues have different oxygen tension, with levels of large intestine as low as 0.5% O2 and up to 13% O2 in the lungs. However, the tissue oxygen levels of many major organs are 3–7%. Under the condition of mammalian cell culture, different degrees of the decline of cell oxygen concentration, such as hypoxia (0.5–2% O2) and severe O2 depletion (anoxic, <0.5% O2) have different degrees of cell damage. In mild hypoxia (4% oxygen), non-cancerous macrophages migration is more related to HIF-1a-PDK1-mediated glycolytic reprogramming, and cytochrome C oxidase activity does not impair, while the decline in mitochondrial oxygen availability may be the result of suppressing cytochrome C oxidase activity in severely hypoxic conditions. Different cellular oxygen concentrations regulate the glucose oxidation through different pathways, which may be the reason for different cellular stress responses. It is reported that moderate hypoxia (2.5% O2) in cultured spermatogonial stem cells can maintain mild ROS levels, which triggers the expression of the anti-apoptotic genes and promotes the proliferation. Osrodek et al. showed that the phenotype of melanoma cells and their response to drugs were different in hyperoxia (21% O2), normoxia (6% O2) and hypoxia (1% O2), which might partly explain the differences between results in vitro and in vivo. Thus, the definition of hypoxia needs to be further regulated for experiments in vitro.

**The role of mitochondria as signaling organelles**

Mitochondria as the main oxygen-consuming organs are a cellular organelle with two membranes. The outer membrane encloses all the contents of the organelle, and the inner membrane and mitochondrial matrix contain many proteins, enzymes, and substrates involved in...
important metabolic reactions. Tricarboxylic acid (TCA) cycle generates the reducing nicotinamide adenine dinucleotide (NADH) and FADH2 via a series of metabolic reactions, which are required to produce ATP through the complexes of electron transport chain (ETC) in the inner mitochondrial membrane. The coupling mechanism between electron transport and ATP formation is known as oxidative phosphorylation (OXPHOS). Mitochondria are the main sites of ROS production, and mROS are generated primarily by complexes I17 and III18 of the ETC, and complex II may also serve as a contributor of ROS under hypoxia19. The balance of mitochondrial fusion and fission regulates mitochondrial morphology network, which is known as mitochondrial dynamics. Mitochondrial fission is regulated by Dynamin-related protein 1 (Drp1) and Dynamin2 (Dnm2), and mitochondrial fusion can be divided into outer membrane fusion and inner membrane fusion, which are mediated by mitofusins 1 and 2 (Mfn1 and Mfn2) and opticatrophy1 (OPA1), respectively20. Damaged mitochondria induce mitochondrial fission under stress, which promote mitophagy and allow them to be cleared by mitophagy.

Mitochondria can support cell reproduction and growth through their role of biosynthesis and bioenergy. However, it has been found over the past two decades that mitochondria play an increasingly important role in determining gene expression profile and controlling signal pathways. In the past, eukaryotic mitochondria, regulated the adaptive response of cells by the production of signal substances such as acetate and ROS, which promote acetylation by acetyl-coA and oxidation of proteins, respectively21. Subsequently, it has been found that mitochondria release more signal components into the cytoplasm to regulate biological functions by affecting the other parts of the cells under hypoxia, including the release of ROS, metabolites, cytochrome C, mitochondrial DNA (mtDNA), and activation of AMPK. Moreover, mitochondrial outer membrane can be used as a signaling platform (Fig. 1).

Mitochondrial-mediated cell death pathway plays an important role in regulation of cardiomyocyte death22. The main event of mitochondrial apoptosis pathway is the increase of mitochondrial outer membrane permeability, which leads to the release of mitochondrial cytochrome C to activate caspases cascade reaction to induce cell death22. Covarrubias et al. demonstrated that Akt-mTORC1 pathway control the production of acetyl-CoA by regulating ATP citrate lyase, which affect the histone acetylation and determine macrophage activation23. In addition, metabolites such as succinate, fumarate, α-ketoglutarate, L-2-HG regulate histone, and DNA demethylation24. Cell stress cause mitochondrial damage and
the release of mtDNA, which enhance pro-inflammatory responses through TLR9 pathway or inflammasome activation. In addition, mtDNA can increase expression of type I IFNs through multiple pathways and mechanisms, which has been comprehensively described elsewhere. Under mild hypoxia, low level production of mROS is important for maintaining normal mitochondrial function. Also, mROS can induce multiple pathways of MitORS under hypoxic conditions, including the Ca²⁺/Calcineurin (Cn) pathway, the HIF pathway, and the AMPK pathway. Chowdhury et al. demonstrated that Ca²⁺/Cn pathway is more sensitive to mROS, partly because of the destruction of mitochondrial membrane potential. AMPK can maintain mitochondrial homeostasis, including the switch of mitochondrial anabolism and catabolism, the regulation of mitochondrial fission/fusion and mitophagy.

**Mitochondria and EVs under hypoxia**

The changes of mitochondria under hypoxia

Hypoxia as a major stressor, has been seen the significant feature of pathological states, such as stroke, tumor, ischemic heart disease, inflammation, obesity, or obstructive sleep apnea. Hypoxia plays a vital role in cell differentiation, inflammation, death by regulating the composition and function of mitochondria. What’s more, mitochondria can also evoke adaptive mechanisms to maintain mitochondrial function in response to hypoxia stress. The TCA cycle can be inhibited under hypoxia, limiting the generation of reducing equivalents, diminishing electron flux through the ETC, which also affects sugar and lipid metabolic pathways. Prolylhydroxylases (PHD) is a receptor and adapter for hypoxia. The loss of PHD activity under hypoxia stabilizes the HIFα. HIF-1α promotes glycolytic reprogramming by inducing pyruvate dehydrogenase kinase, isozyme 1 (PDK1), which inhibits pyruvate dehydrogenase (PDH) to prevent conversion of pyruvate to acetyl-CoA, reducing the TCA cycle flux in mild hypoxia.

Also, sustained hypoxia can decrease ETC activity, although the inhibitory effect of acute hypoxia on ETC may not be obvious. The activity of ETC began to decrease when the intracellular oxygen concentration was 0.3%, which may be related to the high affinity of cytochrome C oxidase (also known as complex IV or COX) for oxygen, so that ETC could maintain ATP levels under anoxia. Fukuda et al. found that hypoxia regulates the switch of COX4 subunits by HIF-1 activation for a more efficient transfer of electrons to O₂ to meet energy demands in mammals.

At the same time, hypoxia-induced moderate mROS has various signaling roles, and mROS needs to be tightly regulated to avoid its overproduction. Cells exposed to hypoxia for a long time will decrease the activity of ETC to limit the production of mROS. However, the inhibition of mROS is limited.

Mitophagy and mitochondrial fission and fusion also play an important role in adaptation to hypoxia. Hypoxic-induced mROS led to the increase in mitochondrial fission, which triggers cisplatin resistance as a process of cellular adaption to the hypoxic tumor microenvironment. Detached cancer cells gather together to cause the hypoxic environment that promotes HIF1α-mediated mitophagy, removing damaged mitochondria, supporting glycolysis, which promotes cancer cell progression. Disruption of metabolic adaptation or cell clusters leads to a decline of the metastatic ability of tumor in vivo. The regulation of mitochondria in tumor cells makes them more tolerant to the hypoxia environment and promotes tumor progression, but targeting mitochondrial function for the therapeutic potential is still controversial because of the non-specifically suppression of anticancer immune responses. Thus, mitochondrial specific targeting therapy still needs a lot of work. In addition, EVs and mitochondrial-derived vesicles (MDVs) can be effective mechanisms to preserve mitochondrial homeostasis, which will be discussed below (Fig. 2).

The change of EVs under hypoxia

Hypoxia affects not only the amount of secreted EVs, but also the contents and corresponding functions. Hypoxic melanoma cells released more EVs than normoxic cells, and hypoxic melanoma EVs showed specific proteins and miRNA characteristics, which might be closely related to the poor prognosis of melanoma patients and might be a potential biomarker for melanoma. Hypoxia tumor cells derived exosomes contain more chemokines, immunosuppressive proteins, and miRNA, which promote tumor progression by regulating phenotypic differentiation of macrophages. Researchers have summarized the molecular mechanisms participated in hypoxia-induced exosomes biogenesis and cargo loading (miRNAs, proteins, and lipids) in cancer cells, including HIF-1α, ceramides, RAB GTPases, ROCK, tetraspanins, oxidative stress. Furthermore, the change of exosomal cargo under hypoxia promotes the communication between tumor cells and stroma, which involved in tumor angiogenesis, survival, proliferation, immunomodulation, invasion, metastasis, and drug resistance. What’s more, the production of EVs under hypoxia also occurs in non-cancerous cells, and HIF1α are key regulators of EVs production under hypoxia. For instance, the release of hypoxic tubular epithelial cells derived miRNA-23a-enriched exosomes is dependent on HIF1α. At the same time, the release of exosomes enriched with miR-216a-5p derived from mesenchymal stem cells (MSCs) under hypoxia was significantly higher than the normoxic conditions, and was also more easily taken up by microglia. Bronchoalveolar
lavage fluid derived miRNA-enriched-EVs may be more likely endocytosed by alveolar macrophages to promote inflammatory response. Therefore, the changes of cargo contained in EVs under hypoxia affect their uptake by target cells. Exosomal miRNA also regulates tissue response to hypoxia. In addition, oxygen concentration can also determine EV release. Exosomes isolated from human cardiac progenitor cells had a significantly increase under physoxia conditions (5% O2) compared with normoxia (21% O2) and hypoxia (1% O2).

**Biology of EVs uptake**

Hypoxia promotes the release of EVs into the extracellular environment, which can be taken up by cells at the distant or nearby. EVs induces functional responses of recipient cells by transferring their contents. The uptake of EVs by receptor cells requires three steps (Fig. 3). The first step of EVs uptake is targeting receptor cells, which may be determined by the source or surface components of EVs, or even the contents of EVs, as well as receptors on the surface of receptor cells. Interacting molecules between EVs and receptor cells are known, including integrins, lipids, tetraspanins, intercellular adhesion molecules etc, which have been systematically reviewed. For example, integrins determine the specificity of tumor cell exosomes targeting metastatic organs. However, exogenous EVs usually lack targeting specificity. Some studies have shown that exogenous EVs enter the body and mainly gather in the liver, lungs, and spleen. Other studies have shown that the targeting specificity of EVs can be increased by modifying EVs. For example, bone marrow MSCs derived exosomes can enhance the specificity and efficiency of targeting ischemic myocardium by engineering ischemic myocardium-targeting peptide, and enhance the therapeutic effect on acute myocardial infarction. Yerneni et al. demonstrated that uptake and targeting specificity of EVs can be specifically altered with a tethered protein via membrane tethering of oligonucleotides, such as functionalizing exosomes with an immunomodulatory protein-FasL. Luo et al. generated an endogenous exosome tracking mouse model to satisfy various research goals, and Verweij et al. developed an zebrafish embryos model to study the biogenesis, composition, journey, and fate of EVs. They found that the large number of yolk syncytial layer exosomes are endocytosed by endothelial cells and macrophages by a combination of imaging methods and proteomic analysis, which highlight the targeting specificity of exosomes. However, the molecular basis for determining the targeting specificity of EVs still needs to be further explored.

The next step of uptake is the combination of EVs with recipient cells. EVs can transmit signals to receptor cells through surface binding, but not deliver contents. EVs isolated from dendritic cells have been shown to activate...
T lymphocyte receptors\textsuperscript{61} or present antigens to T cells via surface contact\textsuperscript{62}. Many studies have shown that EVs can be internalized by receptor cells, including macropinocytosis, phagocytosis, clathrin-dependent pathways, and caveolin-mediated endocytosis, as well as through endocytosis via lipid rafts\textsuperscript{6,63,64}.

The final step is the delivery of contents to the recipient cells and intracellular fate of EVs. The contents of EVs are released to the recipient cells by direct fusion with the plasma membrane\textsuperscript{65,66}. Importantly, the endosomal pathway is also the main pathway for the release of contents\textsuperscript{7}, including EVs-endosome back fusion\textsuperscript{67-69}, the contact of endosomes that contain internalized vesicles with organelles such as nucleus\textsuperscript{70}, the endoplasmic reticulum\textsuperscript{71,72} or mitochondria\textsuperscript{72}. Perhaps the most vital fate of EVs is to target lysosome for degradation, and also possibly be recycled to the plasma membrane. The Placental syncytiotrophoblast EVs were internalized into endosomes and delivered specific miRNAs to the mitochondria or endoplasmic reticulum of recipient cells depending on the state of the source cells of EVs\textsuperscript{72}. Chen et al. demonstrated that anti-angiogenic proteins entered the endosome via endocytosis, and transferred to mitochondria through membrane fusion or kiss-and-run mechanism between late endosome and mitochondria using confocal and super-resolution fluorescent microscopy\textsuperscript{73}. However, the detailed mechanism and the corresponding influencing factors of transmitting EVs contents from endosomes to organelles are still unclear, which is of great significance for in-depth understanding of the intracellular fate and function of EVs.

**The transfer of mitochondria between cells**

It has been found that some cells can secrete EVs containing mitochondria or mitochondrial compositions, such as monocytes\textsuperscript{5}, hepatocytes\textsuperscript{74}, endothelial cells\textsuperscript{75}, and MSCs\textsuperscript{76,77}, and their effect on recipient cells is determined by the activated status of their source of cells.

---

**Fig. 3 Biology of EVs uptake by recipient cells.** (1) EVs mediated intercellular communication requires targeting the receptor cells. (2) In the recipient cell, EVs will bind to the cell surface and initiate intracellular signaling pathways through receptor ligand binding. EVs may also be internalized by acceptor cells through multiple pathways, including macropinocytosis, phagocytosis, clathrin-dependent pathways, caveolin-mediated uptake, and endocytosis via lipid rafts, as well as fuse with the plasma membrane of recipient cells. (3) EVs can release contents to the cytoplasm of the recipient cell by fusion with the plasma membrane and endosome membrane, and also direct transfer into the nucleus, endoplasmic reticulum or mitochondria through the contact of these organelles with endosomes that contain internalized EVs. The most important outcome of EVs is targeted to lysosomal for degradation and also be possibly recycled. SNARE proteins are required for intracellular vesicles fusion.
For instance, damaged mitochondria and composition can be removed by EVs. Researchers believed that the transfer of functional mitochondria or mitochondrial compositions via EVs may increase cellular bioenergetics in ischemic endothelial cells with decreased energy levels to be strategies for treating stroke. Also, EVs derived from MSCs and renal scattered tubular cells have positive effects on recipient cells by transmitting mitochondria. But not all MSCs-derived EVs contain mitochondria. Thomas et al. showed that 25% of MSCs-EVs were positive for mitochondria. In addition, the increased release of EVs containing mitochondrial miR-494-3p and membrane proteins may represent a diagnostic marker for mitochondrial injury. Also, mitochondrial dysfunction in astrocytes can be reflected by depletion of mitochondrial components in EVs, which may also be a diagnostic method. What’s more, lipopolysaccharides activated monocytes induce TNF-α release of free mitochondria, as well as microvesicles enriched in mitochondria, which induce TNF-α and type I interferon-(IFN) signaling pathway, leading to the proinflammatory effects on receptor cells. Moreover, the transfer of mitochondria via exosomes derived from proinflammatory myeloid-derived regulatory cells results in its co-localization with the mitochondrial network of the T cells to produce ROS. Endothelial microparticles (EMP) derived from lipopolysaccharide-treated endothelial cells contain dysfunctional mitochondria, which contributed to the EMPs-mediated inflammatory response. Mitochondrial Lon induced the release of EVs-containing mtDNA, which enhances the M2 macrophages function through the TLR9-dependent pathway and inhibits CD8+ T cell activity, promoting tumor progression. Tsilioni et al. found that EVs-containing mtDNA derived from the serum of patients with autism spectrum disorder promote the secretion of more proinflammatory factor IL-1β in human microglia (Fig. 4).

Also, mitochondrial stress induces the formation of MDVs with sizes from 70 to 150 nm, which have been considered as a pathway of mitochondrial quality control by transferring specific mitochondrial contents into endolysosomal system. In endosomal–lysosomal system, MDVs can fuse with MVEs or lysosomes, and the mitochondrial contents can be secreted to the extracellular space via exosomes or degraded, respectively. The release of MDVs increased under neuronal stress, but the functional significance is still few studied. The pathogenic bacteria induces the production of mROS to promote the bactericidal ability of macrophages, which is delivered to phagosomes by MDVs. Also, MDVs also involve the mitochondrial antigen presentation to trigger the immune response. Therefore, it is reasonable to consider that oxidized mtDNA enters into the endolysosomal pathway through the internalization of EVs or by MDVs, which activates TLR9 Inflammatory pathways and increases the pro-inflammatory gene expression (Fig. 4). Interestingly, exogenous MDVs under different hypoxic conditions mitigated hypoxia-induced myocardial injury and mitochondrial apoptosis via conveying Bcl-2 in vitro. In brief, the contents of MDVs determine the biological effects, depending on the conditions of the cells. A novel high-resolution density gradient is necessary for the further development of EVs and MDVs-related research.

It’s interesting that there are many different ways for the transfer of mitochondria between cells, including tunneling nanotubes (TNTs), exophers, cellular fusion, and GAP junctions. TNTs are membranous channels for cell communication, allowing transport of intercellular signaling and organelles between heterogeneous cells. Many studies have shown that mitochondrial transfer between tumor cells as a mechanism of metabolic adaptation promotes tumorigenesis, invasiveness and metastasis. And preventing the formation of TNTs may be a novel approach to treat cancer. Researchers showed that TNTs formation and the transfer of cargo between neuronal cells are regulated by the Wnt/Ca2+ pathway, thus intervention of Wnt/Ca2+ pathway may be a way to reduce TNTs-caused damage. However, renal CD133+ scattered tubular cells transfer mitochondria through TNTs to injured tubular cells under hypoxia, which plays a cellular protective effect to restore the function of damaged mitochondria. In general, mitochondrial damage may be an important trigger for mitochondrial transfer through TNTs.

Recently, Hayakawa et al. found that stoke induces mitochondria of astrocyte entry to neighboring neurons through extracellular mitochondria particles with the range of sizes from 300 to 1100 nm, which promotes neuronal viability. Lately, some researchers found that exophers (average size 3.8 μM) containing damaged mitochondria extruded by neurons or cardiomyocyte were secreted to extracellular space or cleared by macrophages, which can improve mitochondrial quality control and homeostasis, maintaining the function of neurons and cardiomyocytes, respectively. Thus, the intercellular transfer of mitochondria can be used as an adaptive mechanism to maintain mitochondrial health and improve cellular energetics of hypoxic cells, which may be an effective therapeutic strategy.

The regulation of mitochondria by EVs

Mitochondrial regulation by EVs and their contents

Some studies have shown that changes in mitochondrial function can affect the production and release of EVs. For instance, laminar shear stress caused by aerobic exercise increases the biogenesis of mitochondria via the mechanism of SIRT1/PGC1α dependence, which reduces the production of EVs. Iron overload

Official journal of the Cell Death Differentiation Association
induces mitochondrial damage and apoptosis of endothelial cells, resulting in increased release of EMPs, which can be reduced by decreasing endothelial mitochondrial injury and ROS generation treated with deferiprone\textsuperscript{106}. Moreover, researchers found that mitochondrial function and composition were indirectly affected by the release of EVs, except for the direct regulations under hypoxia. EVs carry a variety of metabolites, proteins, and miRNA to regulate mitochondria of receptor cells, and affect cell differentiation and disease progression. Zhao et al. demonstrated that cancer-related fibroblasts deliver many metabolites to cancer cells via exosomes to provide substances for TCA cycle, promoting cancer progression\textsuperscript{108}. Also, adipocyte EVs deliver proteins and fatty acid substrates to stimulate fatty acid oxidation in melanoma cells, modifying the mitochondrial dynamics, which promotes melanoma migration\textsuperscript{109}. In brief, EVs can regulate mitochondrial
metabolism, biogenesis, mROS, mitophagy and mitochondrial fission and fusion, and the relevant mechanisms will be discussed in detail next (Fig. 5).

The mechanism of mitochondrial regulation by EVs and their contents

**HIF1α/PDK1 pathway**

HIF1α exert an important role in the regulation of mitochondrial metabolism and composition under hypoxia, which has been discussed previously. HIF1α participates in glycolytic pathways and results in the conversion of energy production from OXPHOS to glycolysis. EVs and their active molecules can also target HIF1α to change cell metabolism. EVs derived from tumor-associated macrophages transport a myeloid-specific long noncoding RNA to enhance the aerobic glycolysis by binding PHD2 and preventing the degradation of HIF-1α, which inhibits TCA cycle by inducing PDK1 that inhibits pyruvate dehydrogenase (PDH) activity. (1) EVs activate PGC-1α by directly targeting or through AMPK, which promotes mitochondrial biogenesis by interacting with PPARγ, ERR, or NRF; (2) EVs activate AMPK, which regulates mitophagy and mitochondrial fission by activating ULK1 and directly phosphorylates MFF through DRP1, respectively;

**PGC-1α pathway**

Peroxisome proliferator-activated receptor γ (PPARγ) coactivator 1α (PGC-1α) is a 91 kDa nuclear factor that controls energy homeostasis such as OXPHOS, fatty acid oxidation, and mitochondrial biogenesis by interacting with estrogen-related receptors (ERR), nuclear respiratory factors 1 and 2 (NRF-1/2), PPAR family of transcription factors 1 and 2 (NRF-1/2), PPAR family of transcription factors to regulate mitochondrial genes. M2 derived from hepatocellular carcinoma activates glycolysis via HIF-1α, and induces metabolic reprogramming in monocytes and macrophage differentiation. HIF-1α inhibits mitochondrial oxidation by activating the PDK1, a HIF-1α target gene. It is reported that EVs upregulates miR-302b in the receptor cells, evoking HIF1α/PDK1 pathway to affect glycolysis. Thus, EVs might be a powerful tool for regulating mitochondrial energy metabolism.

**Fig. 5 The mechanism of mitochondrial regulation by EVs.** EVs cause changes in the mitochondrial function of the receptor cells by releasing the contents to the target cells, thus changing the fate of the cells. (1) EVs and their active molecules enhance the glycolysis of recipient cells by binding PHD2 and preventing the degradation of HIF-1α, which inhibits TCA cycle by inducing PDK1 that inhibits pyruvate dehydrogenase (PDH) activity; (2) EVs activate PGC-1α by directly targeting or through AMPK, which promotes mitochondrial biogenesis by interacting with PPARγ, ERRs, or NRF; (3) EVs activate AMPK, which regulates mitophagy and mitochondrial fission by activating ULK1 and directly phosphorylates MFF through DRP1, respectively; (4) EVs affect endoplasmic reticulum stress through Fas ligand receptor pathway, which promotes the production of mitochondrial ROS and ultimately affects mitochondrial function.
the negative influence on PGC-1α. Similarly, the increase of PGC-1α increased endothelial mitochondrial respiration, and improved cell function\textsuperscript{117}, which may also be related to the metastasis of breast cancer\textsuperscript{118}. Recently, it has been found that EVs can also affect phenotypic changes of receptor cells via targeting PGC-1α. For example, EVs secreted by perivascular adipose tissue are enriched in miR-221-3p, which can be delivered to vascular smooth muscle cells (VSMCs) to cause metabolic disorders and mitochondrial dysfunction, causing an early vascular remodeling by targeting PGC-1α\textsuperscript{119}. Similarly, neuronal cells treated with adipose-derived stem cells-exosome showed increase of PGC-1α expression level, recovering mitochondrial function\textsuperscript{120}. During inflammation, PGC-1α dysregulation induces the accumulation of ROS to modify the metabolic properties\textsuperscript{121}, so PGC-1α may be an interesting therapeutic target.

\textit{Adenosine monophosphate-activated protein kinase (AMPK) pathway}

AMPK is not only the sensor and regulator that senses cellular energy\textsuperscript{122}, but also regulates the mitochondrial biology and homeostasis, including mitochondrial biogenesis, mitophagy, and mitochondrial fission/fusion\textsuperscript{29}. Hypoxia leads to mitochondrial damage and cell apoptosis, and also triggers the activation of AMPK to adapt to hypoxia\textsuperscript{123}. AMPK regulates mitochondrial fission by increasing localization of DRP1 depending on the phosphorylation of mitochondrial fission factor (MFF)\textsuperscript{124,125}, and activates autophagy-initiating kinase ULK1 directly to regulate mitophagy\textsuperscript{126}. At sufficient energy levels, the activation of mTORC1 phosphorylated ULK1 to inhibit the AMPK-ULK1 interactions\textsuperscript{127}.

A lncRNA upregulates SIRT1 by sponging miR-29a, promoting the recovery of mitochondrial function in cells of myocardial ischemia-reperfusion injury through activating AMPK/PGC1α signal pathway\textsuperscript{128}. The exosomes secreted by MSCs overexpressed macrophage migration inhibitory factor inhibited mitochondrial fission by activating AMPK, thereby reducing the production of mROS and improving heart function in a rat with myocardial infarction\textsuperscript{129}. Also, HIV-exosomes induce mitochondrial hyperfusion by reducing the phosphorylation of DRP1, and have an detrimental effect on brain endothelial function\textsuperscript{130}. Therefore, finding a suitable target for the intervention of mitochondrial dynamics through EVs may have clinical therapeutic significance.

\textit{Fas/FasL pathway}

Fas receptor is a member of the death receptor family, which exists on the surface of many cells and participates in cell death. Fas has beneficial and harmful effects on the immune cells by the interaction with its ligand FasL. Under different circumstance, and the pathological processes of cells can also be regulated\textsuperscript{131}, ROS plays a key role in regulating cell function, and EVs can induce the production of mROS through Fas/FasL pathway, which leads to cellular dysfunction. EMPs secreted by apoptotic T cells activate neutral sphingomyelinase (SMase) by acting on Fas/FasL to increase cytoplasmic ROS, which activates endoplasmic reticulum (ER) stress, improving the production of mROS through the interaction between ER and mitochondria. When ER stress was inhibited, the production of mROS in endothelial cells treated with MPs decreased and the change of mitochondrial respiration was abolished, indicating that ER stress plays an important role in the production of mROS and the destruction of mitochondrial function, in which Fas receptor plays a key role in the alteration of mitochondrial function induced by EMPs\textsuperscript{132}.

However, the understanding of the mechanism by which EVs regulate mitochondrial function is still limited. HIV-1-infected macrophage-derived exosomal-miR-27a altered the mitochondrial bioenergetics of recipient cells by targeting PPARγ\textsuperscript{133}, and targeting miRNAs may improve lung health. Also, therapeutic targeting of mitochondrial reprogramming may represent strategies to disrupt oncogenic changes, and this reprogramming of mitochondrial dynamics can be induced by hypoxic EVs\textsuperscript{134}. Thus, the combination of targeting specificity of EVs and their enriched cargo to affect the mitochondrial homeostasis of receptor cells can be expected to gain greater attraction in the future.

\textbf{Significance of mitochondria regulated by EVs in hypoxic diseases}

\textbf{Significance for hypoxic/ischemic injury}

Ischemia is a disruption of blood flow in tissue, resulting in the lack of oxygen. Ischemic injury includes traumatic hemorrhage, stoke, ischemic heart disease, acute kidney injury (AKI), organ transplantation, and others. The increase of mROS and mitochondrial fission are the important causes of hypoxic/ischemic injury, which can be regulated by EVs and their contents. For instance, plasma exosomes attenuate mitochondrial damage and inhibits the production of ROS by transferring HSP70 to the cerebral ischemia/reperfusion (I/R) injury area\textsuperscript{135}. MSC-exosomes inhibits mitochondrial fission to improve heart function in myocardial infarction mouse model\textsuperscript{129}. Similarly, MSC-derived EVs inhibit mitochondrial fission via the transfer of miR-30, which reduces apoptosis and alleviates renal I/R injury. These effects are reduced when miR-30 was inhibited, indicating that EVs-miRNA may be used as a diagnostic marker\textsuperscript{136}. Also, the same effect was observed in exosomes carrying miR-210\textsuperscript{137}. EVs-miRNA-200a-3p secreted by MSCs improve the mitochondrial function of tubular epithelia cells in renal I/R injury via acting on the Keap1-Nrf2 signaling pathway\textsuperscript{138}. As the
main organelle affected by ischemia/hypoxia injury, mitochondria can be used as the targets of EVs, so as to provide ideas in the diagnosis and treatment of diseases.

Significance for hypoxic tumor diseases
Mitochondria play an important role in cancer through energy production, signal transmission and quality control. As early as 1956, Warburg suggested that cancers would maintain high glycolytic capacity in the presence of oxygen, which called aerobic glycolysis, and mitochondria were thought to be mere bystanders of cancer progression\textsuperscript{139}, and then researchers gradually found out that mitochondria exert the vital effects on tumor metabolism, calcium homeostasis and control redox, oncogenic signaling, and cell death, besides supplying energy, which is closely associated with malignant tumor progression\textsuperscript{2,38}. In addition, mitochondrial function can be regulated by hypoxia tumor exosomes. Park et al.\textsuperscript{44}, found that exosomes-let-7a miRNA derived from hypoxic tumor cells enhanced OXPHOS in macrophages, favoring tumor development. Normal mammary epithelial cell treated with EVs derived from hypoxic human breast cancer cells activates Ser616 phosphorylation of DRP1 and increases the expression of MFN1 and MFN2 with mitochondria, and stimulates mitochondrial fission and fusion events, which is positively correlated with cell migration\textsuperscript{134}. Also, Clement et al. demonstrated that increased gene expression of mitochondrial dynamics (FIS1, MFN2, and OPA1) correlated with decreased overall survival in melanoma patients, which can be provoked by the adipocytes via EVs, and promoting melanoma aggressiveness\textsuperscript{109}. Resistant breast cancer cells derived EVs transported Hsp70 into mitochondria, enhancing adriamycin resistance\textsuperscript{140}. Moreover, exosomes regulate multiple malignant changes by reprogramming of mitochondrial metabolism via shuttling metabolic related substances\textsuperscript{108,109,111,141}, thus preventing EVs from transporting cargo might be an effective strategy for regulating mitochondria and cancer metastasis and progression.

Prospects
In this review, we summarized the changes of mitochondria under hypoxia, and the role of mitochondria as signal organelles in regulating cellular phenotypic differentiation, inflammation and death. Mitochondria can maintain a stable state under hypoxia through mitochondrial quality control mechanism, such as mitochondrial metabolic homeostasis, mitophagy, mitochondrial fission and fusion, EVs, MDVs, as well as mitochondrial transfer via multiple pathways. Mitochondrial function could be regulated indirectly by EVs via the delivery of contents under hypoxia, facilitating tumor progression and ischemic damage. The delivery of mitochondria or mtDNA via EVs between cells under stress causes inflammatory response in the recipient cells. In addition, EVs derived from MSCs and some normal cells have a protective effect on mitochondria of recipient cells. Drugs have been used in tumors and metabolic diseases by regulating mitochondrial biosynthesis and metabolism, but there still are lack of clinical studies on EVs regulate mitochondrial function.

Although researchers have shown that EVs play an important role in the regulation of mitochondria, the specific substances contained in EV and whether these substances enter directly into the mitochondria of recipient cells are still unclear. Exosomes and microvesicles can be distinguished because of their different positions of origin and sizes, and their biogenetic mechanisms are similar but also different. And it is unclear whether their roles in the regulation of mitochondria are also different\textsuperscript{76}. Better tracking models, monitoring methods and isolation techniques are the basis for further research. Anyway, this review will provide ideas for the research on the intervention of mitochondrial function through EVs.

Acknowledgements
This research was funded by National Natural Science Foundation of China (Grant No. 81970085 and 81670086), the Tianjin Science and Technology Plan Project (Grant No. 17ZXMFSY00080).

Author contributions
Yaodan Zhang, Qiang Zhang, and Jin Tan conceived and designed the manuscript. Yaodan Zhang wrote the paper. Yuyang Miao contributed to the language modification and guidance. All authors confirmed the final version of the manuscript for submission.

Funding
National Natural Science Foundation of China (Grant No. 81970085 and 81670086). The Tianjin Science and Technology Plan Project (Grant No. 17ZXMFSY00080).

Conflict of interest
The authors declare no competing interests.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 24 November 2020 Revised: 12 March 2021 Accepted: 15 March 2021
Published online: 06 April 2021

References
1. Fuhrmann, D. C. & Brune, B. Mitochondrial composition and function under the control of hypoxia. Redox Biol. 12, 208–215 (2017).
2. Zong, W. X., Rabkinowitz, J. D. & White, E. Mitochondria and cancer. Mol. Cell 61, 667–676 (2016).
3. Ham, P. B. 3rd & Raju, R. Mitochondrial function in hypoxic ischemic injury and influence of aging. Prog. Neurobiol. 157, 92–116 (2017).
4. Wheaton, W. W. et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife 3, e02242 (2014).
5. Scharping, N. E., Menke, A. V., Whetstone, R. D., Zeng X. & Delgoffe, G. M. Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia. Cancer Immunol. Res. 2017, 5, 9–16 (2017).
6. van Niel, G., D’Angelo, G. & Raposo, G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 19, 213–228 (2018).

7. Mattei, M., Martin-Jau, L., Lavieu, G. & Théry, C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat. Cell Biol. 21, 9–17 (2019).

8. Colombo, M., Raposo, G. & Théry, C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 30, 255–289 (2014).

9. Puhn, F. et al. Mitochondria are a subset of extracellular vesicles released by activated monocyes and induce type I IFN and TNF responses in endothelial cells. Curr. Res. 125, 43–52 (2019).

10. Morrison, T. J. et al. Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer. Am. J. Respir. Crit. Care Med. 196, 1275–1286 (2017).

11. Jain, R. K. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26, 605–622 (2014).

12. Aszt, T. & Moota, V. K. Oxygen and mammalian cell culture: a renewed repeating homeostasis. J. Physiol. 597, 1495–1507 (2020).

13. Lee, P., Chandel, N. S. & Simon, M. C. Cellular adaptation to hypoxia through Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation. Int. J. Mol. Sci. 20, 4023 (2019).

14. Herzig, S. & Shaw, R. J. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat. Rev. Mol. Cell Biol. 11, 176–182 (2010).

15. Bargiela, D., Burr, S. P. & Chinnery, P. F. Mitochondria and hypoxia: metabolic cross-talk in cell-fate decisions. Trends Endocrinol. Metab. 29, 249–259 (2018).

16. Mehta, M. M., Weinberg, S. E. & Chandel, N. S. Mitochondrial control of immunity: beyond ATP. Nat. Rev. Immunol. 17, 608–620 (2017).

17. Wilson, D. F., Runsey, W. L., Green, T. J. & Vanderkooi, J. M. The oxygen dependence of mitochondrial oxidative phosphorylation measured by a new optical method for measuring oxygen concentration. J. Biol. Chem. 263, 2717–2718 (1988).

18. Fukuda, R. et al. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129, 111–122 (2007).

19. Kim, J.-W. et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3, 177–185 (2006).

20. Eisinger, V., Picard, M. & Hainzöck, G. Mitochondrial dynamics in adaptive and maladaptive cellular stress responses. Nat. Cell Biol. 20, 755–765 (2018).

21. Han, Y. et al. Mitochondrial fusion causes cislipid resistance under hypoxic conditions via ROS in ovarian cancer cells. Oncogene 38, 7089–7105 (2019).

22. Labuschagne, C. F., Cheung, E. C., Blagih, J., Donart, M. C. & Vouwen, K. H. Cell clustering promotes a metabolic switch that supports metastatic colonization. Cell Metab. 30, 720–734 (2019).

23. Porporato, P. E., Filigheddu, N., Pedro, J. M. B., Kroemer, G. & Galluzzi, L. Mitochondrial metabolism and cancer. Cell Res. 28, 265–280 (2018).

24. Pica, A. et al. Mitochondrial dysfunction and aging: insights from the analysis of extracellular vesicles. Int. J. Mol. Sci. 20, 805 (2019).

25. Leemakers, P. A. et al. Iron deficiency-induced loss of skeletal muscle mitochondrial proteins and respiratory capacity: the role of mitophagy and secretion of mitochondria-containing vesicles. FASEB J. 34, 6703–6717 (2020).

26. Picca, A. et al. Generation and release of mitochondrion-derived vesicles in Drosophila aging and disease. J. Clin. Med. 2020, 9, 1440 (2020).

27. Walbr ogó, G. et al. Hypoxia-induced adaptations of miRNome and proteomes in melanoma cells and their secreted extracellular vesicles. Cancers 12, 692 (2020).

28. Chen, X. et al. Exosomes derived from hypoxic epithelial ovarian cancer cells deliver microRNAs to macrophages and elicit a tumor-promoted phenotype. Cancer Lett. 435, 80–91 (2019).

29. Park, J. E. et al. Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift. Oncogene 38, 5158–5173 (2019).

30. Kumar, A. & Deep, G. Hypoxia in tumor microenvironment regulates exosome biogenesis: Molecular mechanisms and translational opportunities. Cancer Lett. 479, 23–30 (2020).

31. Meng, W., Hao, Y., He, C., Li, L. & Zhu, G. Exosome-orchestrated hypoxic tumor microenvironment. Mol. Cancer 18, 57 (2019).

32. Kumar, A. & Deep, G. Exosomes in hypoxia-induced remodeling of the tumor microenvironment. Cancer Lett. 488, 1–8 (2020).

33. Shao, C. et al. Role of hypoxia-induced exosomes in tumor biology. Mol. Cancer 17, 120 (2018).

34. Choudhry, H. & Harris, A. L. Advances in hypoxia-inducible factor biology. Nat. Rev. Cancer 19, 304–312 (2019).

35. Choudhry, H. & Harris, A. L. Advances in hypoxia-inducible factor biology. Nat. Rev. Cancer 19, 304–312 (2019).

36. Wang, X. et al. Engineered exosomes with ischemic myocardium deliver microRNAs to macrophages and elicit a tumor-promoted phenotype. Nat. Rev. Cardiol. 17, 517–528 (2019).

37. Haimi, M. et al. Exosomal miR-23a regulates mitochondrial metabolism in cancer cells. Cell Death and Disease 10, 1–10 (2019).

38. Haimi, M. et al. Exosomal miR-23a regulates mitochondrial metabolism in cancer cells. Cell Death and Disease 10, 1–10 (2019).

39. Haimi, M. et al. Exosomal miR-23a regulates mitochondrial metabolism in cancer cells. Cell Death and Disease 10, 1–10 (2019).

40. Haimi, M. et al. Exosomal miR-23a regulates mitochondrial metabolism in cancer cells. Cell Death and Disease 10, 1–10 (2019).

41. Haimi, M. et al. Exosomal miR-23a regulates mitochondrial metabolism in cancer cells. Cell Death and Disease 10, 1–10 (2019).

42. Haimi, M. et al. Exosomal miR-23a regulates mitochondrial metabolism in cancer cells. Cell Death and Disease 10, 1–10 (2019).

43. Haimi, M. et al. Exosomal miR-23a regulates mitochondrial metabolism in cancer cells. Cell Death and Disease 10, 1–10 (2019).

44. Haimi, M. et al. Exosomal miR-23a regulates mitochondrial metabolism in cancer cells. Cell Death and Disease 10, 1–10 (2019).

45. Haimi, M. et al. Exosomal miR-23a regulates mitochondrial metabolism in cancer cells. Cell Death and Disease 10, 1–10 (2019).

46. Haimi, M. et al. Exosomal miR-23a regulates mitochondrial metabolism in cancer cells. Cell Death and Disease 10, 1–10 (2019).

47. Haimi, M. et al. Exosomal miR-23a regulates mitochondrial metabolism in cancer cells. Cell Death and Disease 10, 1–10 (2019).

48. Haimi, M. et al. Exosomal miR-23a regulates mitochondrial metabolism in cancer cells. Cell Death and Disease 10, 1–10 (2019).

49. Haimi, M. et al. Exosomal miR-23a regulates mitochondrial metabolism in cancer cells. Cell Death and Disease 10, 1–10 (2019).

50. Haimi, M. et al. Exosomal miR-23a regulates mitochondrial metabolism in cancer cells. Cell Death and Disease 10, 1–10 (2019).

51. Haimi, M. et al. Exosomal miR-23a regulates mitochondrial metabolism in cancer cells. Cell Death and Disease 10, 1–10 (2019).

52. Haimi, M. et al. Exosomal miR-23a regulates mitochondrial metabolism in cancer cells. Cell Death and Disease 10, 1–10 (2019).

53. Haimi, M. et al. Exosomal miR-23a regulates mitochondrial metabolism in cancer cells. Cell Death and Disease 10, 1–10 (2019).

54. Haimi, M. et al. Exosomal miR-23a regulates mitochondrial metabolism in cancer cells. Cell Death and Disease 10, 1–10 (2019).

55. Haimi, M. et al. Exosomal miR-23a regulates mitochondrial metabolism in cancer cells. Cell Death and Disease 10, 1–10 (2019).

56. Haimi, M. et al. Exosomal miR-23a regulates mitochondrial metabolism in cancer cells. Cell Death and Disease 10, 1–10 (2019).

57. Haimi, M. et al. Exosomal miR-23a regulates mitochondrial metabolism in cancer cells. Cell Death and Disease 10, 1–10 (2019).
62. Zinovog, L. et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. *Nat. Med.* **4**, 594–600 (1998).
63. Mulcahy, L. A., Pink, R. C. & Carter, D. R. Routes and mechanisms of extra-cellular vesicle uptake. *J. Extracell. Vesicles* **3**, 24641 (2014).
64. Mohning, M. P. et al. Phagocytosis of microparticles by alveolar macrophages during acute lung injury requires MerTK. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **314**, L69–L82 (2018).
65. Parolini, I. et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. *J. Biol. Chem.* **284**, 34211–34222 (2009).
66. Montecalvo, A. et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. *Blood* **119**, 756–766 (2012).
67. Yao, Z. et al. Exosomes exploit the virus entry machinery and pathway to transmit alpha interferon-induced antiviral activity. *J. Virol.* **82**, 24 (2018).
68. Joshi, B. S., de Beer, M. A., Giepmans, B. N. G. & Zuhorn, I. S. Endocytosis of extracellular vesicles and release of their Cargo from endosomes. *ACS Nano* **14**, 4444–4455 (2020).
69. Bisig, C. & Gruenberg, J. ALIX and the multivesicular endosome: ALIX in Wonderland. *Trends Cell Biol.* **24**, 19–25 (2014).
70. Sanquist, M. P. et al. VAMP-associated protein-A and oxycteol-binding protein-related protein 3 promote the entry of late endosomes into the nuclear-plasmic reticulum. *J. Biol. Chem.* **293**, 13834–13848 (2018).
71. Heusermann, V. et al. Exosomes surf on filopodia to enter cells at endocytic hot spots, traffic within endosomes, and are targeted to the ER. *J. Cell Biol.* **213**, 173–184 (2016).
72. Cronquiost, T. et al. Synctiotrophoblast derived extracellular vesicles transfer functional placental miRNAs to primary human endothelial cells. *Sci. Rep.* **7**, 4558 (2017).
73. Chen, M. et al. Extracellular anti-angiogenic proteins augment an endosomal protein trafficking pathway to reach mitochondrion and execute apoptosis in HUVECs. *Cell Death Differ.* **25**, 1905–1920 (2018).
74. Gao, Y. et al. Mitochondrial DNA-enriched microparticles promote acute-on-chronic alcoholic nephropathy and hepatotoxicity. *JCI Insight* **2**, e90634 (2017).
75. Tripathi, D. et al. Proinflammatory effect of endothelial microparticles is mediated and modulated through MAPKAPK2 (MAPK-Activated Protein Kinase 2) leading to attenuation of cardiac hypertrophy. *Annals. Thorac. Vasc. Biol.* **39**, 1100–1112 (2019).
76. Phinney, D. G. et al. Mesenchymal stem cells use extracellular vesicles to outreach mtorgolys and shuffle miRNAs. *Nat. Commun.* **6**, 8472 (2015).
77. Silva, J. D. et al. MSC extracellular vesicles rescue mitochondrial dysfunction and improve barrier integrity in clinically relevant models of ARDS. *Eur Respir J.* **2002978** (2020). https://doi.org/10.1183/13993003.02978-2020.
78. D’Souza, A., Dave, K. M., Steffler R. A., Manickam D. S. Targeting the blood-brain barrier for the delivery of stroke therapies. *Adv. Drug Deliv. Rev.* **171**, 332–351 (2021).
79. Zhou, X. et al. Renal scattered tubular-like cells confer protective effects in the stenotic murine kidney mediated by release of extracellular vesicles. *Sci. Rep.* **8**, 1265 (2018).
80. Ahn, J. Y. et al. Release of extracellular vesicle miR-494-3p by ARPE-19 cells with impaired mitochondria. *Biochim. Biophys. Acta 1865*, 129936 (2020).
81. Jiang, S. C. et al. Mitochondrial protein enriched extracellular vesicles secreted from astrocytes in a mouse model of fragile X syndrome. *Front. Cell Dev. Biol.* **8**, e102525 (2020).
82. Ahn, J. Y. et al. Mitochondria-derived vesicles protect Cardiomyocytes against ischemic reperfusion injury. *Front. Physiol.* **11**, e00585 (2021).
83. Jang, S. C. et al. Mitochondrial protein enriched extracellular vesicles deliver antimicrobial reactive oxygen species to control phagosome-localized *Staphylococcus aureus*. *Cell Host Microbe* **24**, 625–636 (2018).
84. Mathieuoxd, D. et al. PARKinson’s disease-related proteins PARK1 and PARK2 repress mitochondrial antigen presentation. *Cell 166*, 314–327 (2016).
85. Li, B. et al. Mitochondrial-derived vesicles promote Cardiomyocytes against hypoxic damage. *Front. Cell Dev. Biol.* **8**, 214 (2020).
86. D’Azzaro, P. et al. Mitovescicles are a novel population of extracellular vesicles of mitochondrial origin altered in Down syndrome. *Sci. Adv.* **7**, eabe5085 (2021).
87. Hayakawa, K. et al. Transfer of mitochondria from astrocytes to neurons after stroke. *Nature* **535**, 551–555 (2016).
88. Torralba, D., Baixauli, F. & Sanchez-Madrid, F. Mitochondria know no boundaries: mechanisms and functions of intercellular mitochondrial transfer. *Front. Cell Dev. Biol.* **10**, 107 (2021).
89. Lu, J. et al. Tunneling nanotubes promote intercellular mitochondrial transfer following increased invasiveness in bladder cancer cells. *Oncoarget* **8**, 15539–15552 (2017).
90. Tan, A. S. et al. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. *Cell Metab.* **21**, 81–94 (2015).
91. Roehlecke, C. & Schmidt, M. H. H. Tunneling nanotubes and tumor microvesicles in cancer. *Cancers* **12**, 857 (2020).
92. Burt, R. et al. Activated stromal cells transfer mitochondria to rescue acute lymphocytic leukemia cells from oxidative stress. *Blood* **134**, 1415–1429 (2019).
93. Lou, E. The implications of direct intercellular communication tunneling nanotubes in peritoneal and other invasive malignancies. *Front. Oncol.* **10**, 599548 (2020).
94. Vargas, J. Y. et al. The Wnt/Ca pathway is involved in intermenusal communication mediated by tunneling nanotubes. *EMBO J.* **38**, e101230 (2019).
95. Zou, X. et al. Mitochondria transfer via tunneling nanotubes is an important mechanism by which CD133+ scattered tubular cells eliminate hypoxic tubular cell damage. *Biochim. Biophys. Res. Commun.* **522**, 205–212 (2020).
96. Melentijevic, I. et al. C. elegans neurons jettison protein aggregates and mitochondria under neurotropic stress. *Nature* **542**, 367–371 (2017).
97. Nicolas-Avila, J. A. et al. A network of macrophages supports mitochondrial homeostasis in the heart. *Cell 183*, 94–109 (2020).
98. Kim, J. S. et al. Shear stress-induced mitochondrial biogenesis decreases the release of microparticles from endothelial cells. *Am. J. Physiol. Heart Circ. Physiol.* **309**, H1425–H1433 (2015).
99. Chan, S. et al. Defenrione inhibits iron overload-induced tissue factor bearing endothelial microvascular generation by inhibition oxidative stress induced mitochondrial injury, and apoptosis. *Toxicol. Appl. Pharmacol.* **338**, 148–158 (2018).
100. Kogodage, U. S. et al. Cannabinol (CBD) is a novel inhibitor for exosome and microvesicle (EMV) release in cancer. *Front. Pharmacol.* **9**, 889 (2018).
101. Zhao, H. et al. Tumor microenvironment derived exosomes plastically modulate cancer cell metabolism. *eLife* **5**, e01250 (2016).
102. Clement, E. et al. Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial metabolism and remodeling in tumor cells. *EMBO J.* **39**, e102525 (2020).
103. Chen, F. et al. Extracellular vesicle-packaged HIF-1alpha-stabilizing IncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. *Nat. Cell Biol.* **21**, 498–510 (2019).
104. Hou, P. et al. Ectosomal PDMD2 promotes HCC by inducing macrophage differentiation and remodeling the tumor microenvironment. *Mol. Cell. Biol.* **78**, 1192–1206 (2020).
105. Takahashi, K., Yan, I. K., Haga, H. & Patel, T. Modulation of hypoxia-signalling pathways by extracellular linc-RoR. *J. Cell Sci.* **127**, 1585–1594 (2014).
106. Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L. & Denko, N. C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. *Cell Metab.* **3**, 187–197 (2006).
107. Mas-Bargues, C. et al. Extracellular vesicles from healthy cells improves cell function and stemness in premature senescent stem cells by miR-302b and HIF-1 alpha activation. *Biomolecules* **10**, 957 (2020).
108. Cheng, C. F., Ku, H. C. & Lin, H. P. -G.1alpha as a pivotal factor in lipid and metabolic regulation. *Int. J. Mol. Sci.* **19**, 3447 (2018).
116. Eichner, L. J. & Giguère, V. Estrogen related receptors (ERs): a new dawn in transcriptional control of mitochondrial gene networks. *Mitochondrion* **11**, 544–552 (2011).

117. Ye, J. X., Wang, S. S., Ge, M. & Wang, D. J. Suppression of endothelial PGC-Talp alpha is associated with hypoxia-induced endothelial dysfunction and provides a new therapeutic target in pulmonary arterial hypertension. *Am. J. Physiol. Lung Cell Mol. Physiol.* **310**, L1233–L1242 (2016).

118. Andrzewska, S. et al. PGC-1α1 promotes breast cancer metastasis and confers bioenergetic flexibility against metabolic drugs. *Cell Metabol.* **26**, 778–787 (2017).

119. Li, X., Ballantyne, L. L., Yu, Y. & Funk, C. D. Perivascular adipose tissue-derived extracellular vesicle miR-29a to activate the SIRT1/AMPK/PGC1alpha pathway. *FASEB J.* **33**, 12704–12722 (2019).

120. Lee, M. et al. Adipose-derived stem cell exosomes alleviate pathology of amyotrophic lateral sclerosis in vitro. *Biochim. Biophys. Res. Commun.* **479**, 434–439 (2016).

121. Rius-Pérez, S., Torres-Cuevas, I., Millán, I., Ortega, A. L. & Pérez, S. PGC-1, inflammation, and oxidative stress: an integrative view in metabolism. *Oxid. Med. Cell Longev.* **2020**, 1452666 (2020).

122. Kraus, F. & Ryan, M. T. The constriction and scission machineries involved in mitochondrial fission. *J. Cell Sci.* **130**, 2953–2960 (2017).

123. Zhang, H. et al. AMPK activation serves a critical role in mitochondria quality control via modulating mitophagy in the heart under chronic hypoxia. *Int. J. Mol. Med.* **41**, 69–76 (2018).

124. Kraus, F. & Ryan, M. T. The constriction and scission machineries involved in mitochondrial fission. *J. Cell Sci.* **130**, 2953–2960 (2017).

125. Toyama, E. Q. et al. Metabolism. AMP-activated protein kinase mediates mitochondrial fission in response to energy stress. *Science* **351**, 275–281 (2016).

126. Egan, D. F. et al. Phosphorylation of ULK1 (HATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. *Science* **331**, 456–461 (2011).

127. Kim, J., Kundu, M., Violett, B. & Guan, K. L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nat. Cell Biol.* **13**, 132–141 (2011).

128. Niu, X. et al. IncRNA Oip5-as1 attenuates myocardial ischaemia/reperfusion injury by sponging miR-29a to activate the SIRT1/AMPK/PGC-Talp alpha pathway. *Cell Prolif.* **53**, e12818 (2020).

129. Liu, X. et al. Exosomes from mesenchymal stem cells overexpressing PIM enhance myocardial repair. *J. Cell Physiol.* **235**, 8010–8022 (2020).

130. Chandra, P. K. et al. Latent HIV-exosomes induce mitochondrial hyperfusion due to loss of phosphorylated dynamin-related protein 1 in brain endothelium. *Mol. Neurobiol.* (2021). https://doi.org/10.1007/s12035-021-02319-8.

131. Yamada, A., Araki, R., Saito, M., Kudo, Y. & Ishimaru, N. Dual role of Fas/FasL-mediated signal in peripheral immune tolerance. *Front. Immunol.* **8**, 403 (2017).

132. Saffiedeen, Z. et al. Temporal cross talk between endoplasmic reticulum and mitochondria regulates oxidative stress and mediates microparticle-induced endothelial dysfunction. *Antioxid. Redox Signal.* **26**, 15–27 (2017).

133. Yuan, Z. et al. Macrophages exposed to HIV viral protein disrupt lung epithelial cell integrity and mitochondrial bioenergetics via exosomal microRNA shuttling. *Cell Death Dis.* **10**, 580 (2019).

134. Bertolini, I. et al. Small extracellular vesicle regulation of mitochondrial dynamics reprograms a hypoxic tumor microenvironment. *Dev. Cell* **55**, 163–177 (2020).

135. Jiang, Y., He, R., Shi, Y., Liang, J. & Zhao, L. Plasma exosomes protect against cerebral ischemia/reperfusion injury via exosomal HSP70 mediated suppression of ROS. *Life Sci.* **256**, 117987 (2020).

136. Gu, D. et al. Mesenchymal stromal cells derived extracellular vesicles ameliorate acute renal ischemia reperfusion injury by inhibition of mitochondrial fission through miR-30. *Stem Cells Int.* **2016**, 2093940 (2016).

137. Ma, X. et al. Loading MiR-210 in endothelial progenitor Cells derived exosomes boosts their beneficial effects on hypoxia/reoxygenation-injured human endothelial cells via protecting mitochondrial function. *Cell Physiol. Biochem.* **46**, 664–675 (2018).

138. Cao, H. et al. In vivo tracking of mesenchymal stem cell-derived extracellular vesicles improving mitochondrial function in renal ischemia-reperfusion injury. *ACS Nano* **14**, 4014–4026 (2020).

139. Warburg, O. On the origin of cancer cells. *Science* **123**, 309–314 (1956).

140. Hu, W. et al. Small extracellular vesicle-mediated Hsp70 intercellular delivery enhances breast cancer Adriamycin resistance. *Free Radic. Biol. Med.* **164**, 85–95 (2021).

141. Wang, D. et al. Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2. *Theranostics* **11**, 2860–2875 (2021).